university website

Dhami, S. (S.), Nurmatov, U. (U.), Arasi, S. (S.), Khan, T. (T.), Asaria, M. (M.), Zaman, H. (H.), Agarwal, A. (A.), G. Netuveli (Gopalakrishnan), G. Roberts, O. Pfaar (Oliver), et al. Muraro, A. (A.), I.J. Ansotegui (I.), M. Calderon (Moises), Cingi, C. (C.), S.R. Durham (Stephen), R. Gerth van Wijk (Roy), S. Halken (Susanne), Hamelmann, E. (E.), P.W. Hellings (Peter), L. Jacobsen, E.F. Knol (Edward Frank), D. Larenas-Linnemann (Désirée), Lin, S. (S.), Maggina, P. (P.), R. Mösges (Ralph), H.N.G. Oude Elberink (Hanneke N.G.), G. Pajno (G.), Panwankar, R. (R.), Pastorello, E. (E.), Penagos, M. (M.), C. Pitsios, Rotiroti, G. (G.), Timmermans, F. (F.), Tsilochristou, O. (O.), E.M. Varga, C.B. Schmidt-Weber, Wilkinson, J. (J.), Williams, A. (A.), M. Worm (M.), Zhang, L. (L.) and A. Sheikh (Aziz)

2017

Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis

Publication

Publication

Allergy , Volume 72 - Issue 11 p. 1597- 1631

Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis. To inform the development of clinical recommendations, we undertook a systematic review to assess the effectiveness, cost-effectiveness, and safety of AIT in the management of allergic rhinoconjunctivitis. Methods: We searched nine international biomedical databases for published, in-progress, and unpublished evidence. Studies were independently screened by two reviewers against predefined eligibility criteria and critically appraised using established instruments. Our primary outcomes of interest were symptom, medication, and combined symptom and medication scores. Secondary outcomes of interest included cost-effectiveness and safety. Data were descriptively summarized and then quantitatively synthesized using random-effects meta-analyses. Results: We identified 5960 studies of which 160 studies satisfied our eligibility criteria. There was a substantial body of evidence demonstrating significant reductions in standardized mean differences (SMD) of symptom (SMD −0.53, 95% CI −0.63, −0.42), medication (SMD −0.37, 95% CI −0.49, −0.26), and combined symptom and medication (SMD −0.49, 95% CI −0.69, −0.30) scores while on treatment that were robust to prespecified sensitivity analyses. There was in comparison a more modest body of evidence on effectiveness post-discontinuation of AIT, suggesting a benefit in relation to symptom scores. Conclusions: AIT is effective in improving symptom, medication, and combined symptom and medication scores in patients with allergic rhinoconjunctivitis while on treatment, and there is some evidence suggesting that these benefits are maintained in relation to symptom scores after discontinuation of therapy.

Additional Metadata
Keywords allergen, allergen immunotherapy, allergic rhinoconjunctivitis, subcutaneous, sublingual
Persistent URL doi.org/10.1111/all.13201, hdl.handle.net/1765/108630
Journal Allergy
Grant This work was funded by the European Commission 7th Framework Programme; grant id fp7/601763 - AN INNOVATIVE CAUSAL THERAPY FOR ALLERGY: SAFE AND RAPID INDUCTION OF AN ANTI-INFLAMMATORY IMMUNE RESPONSE USING A MUTANT HYPOALLERGEN AND VITAMIN D3 (BM4SIT)
Organisation Erasmus MC: University Medical Center Rotterdam
Citation
Dhami, S. (S.), Nurmatov, U. (U.), Arasi, S. (S.), Khan, T. (T.), Asaria, M. (M.), Zaman, H. (H.), … Sheikh, A. (2017). Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy (Vol. 72, pp. 1597–1631). doi:10.1111/all.13201


User Publication Person Organisation Collection
Close